Unknown

Dataset Information

0

Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestion.


ABSTRACT: Monoclonal antibodies are subjected to a wide variety of post-translational modifications (PTMs) that cause structural heterogeneity. Characterization and control of these modifications or quality attributes are critical to ensure antibody quality and to define any potential effects on the ultimate safety and potency of antibody therapeutics. The biopharmaceutical industry currently uses numerous tools to analyze these quality attributes individually, which requires substantial time and resources. Here, we report a simple and ultrafast bottom-up liquid chromatography-mass spectrometry (uLC-MS) method with 5 min tryptic digestion to simultaneously analyze multiple modifications, including oxidation, deamidation, isomerization, glycation, glycosylation, and N-terminal pyro-glutamate formation, which can occur during antibody production in mammalian cell culture, during purification and/or on storage. Compared to commonly used preparation procedures, this uLC-MS method eliminates assay artifacts of falsely-increased Met oxidation, Asp isomerization, and Asn deamidation, a problem associated with long digestion times in conventional LC-MS methods. This simple, low artifact multi-attribute uLC-MS method can be used to quickly and accurately analyze samples at any stage of antibody drug development, in particular for clone and media selection during cell culture development.

SUBMITTER: Wang Y 

PROVIDER: S-EPMC5098434 | biostudies-literature | 2016 Nov/Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestion.

Wang Yi Y   Li Xiaojuan X   Liu Yan-Hui YH   Richardson Daisy D   Li Huijuan H   Shameem Mohammed M   Yang Xiaoyu X  

mAbs 20160906 8


Monoclonal antibodies are subjected to a wide variety of post-translational modifications (PTMs) that cause structural heterogeneity. Characterization and control of these modifications or quality attributes are critical to ensure antibody quality and to define any potential effects on the ultimate safety and potency of antibody therapeutics. The biopharmaceutical industry currently uses numerous tools to analyze these quality attributes individually, which requires substantial time and resource  ...[more]

Similar Datasets

| S-EPMC6343770 | biostudies-literature
| S-EPMC5431074 | biostudies-literature
| S-EPMC7175258 | biostudies-literature
| S-EPMC6836746 | biostudies-literature
| S-EPMC7096717 | biostudies-literature
| S-EPMC9252900 | biostudies-literature
| S-EPMC6152450 | biostudies-literature
| S-EPMC5587545 | biostudies-literature
| S-EPMC8342516 | biostudies-literature
| S-EPMC6333165 | biostudies-other